Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADXS did a 1-125 reversal within the last 18 months... http://www.businesswire.com/news/home/20130716005516/en/Update-Advaxis-Announces-1-for-125-Reverse-Stock-Split
ADXS PTs will be tapered, the deals they made with PETX and Merck were underwhelming IMO. The PETX deal is the best thing they have going currently.
Been following ADXS for close to two years now. They have a terrible track record with shareholders, one being a 125 to 1 reverse split in July 2013, the other being countless dilution's including the one that just occurred in March at $3.00.
( http://uk.reuters.com/article/2014/03/31/idUKnGNX15TGgq+1cc+GNW20140331 )
With that said, newly appointed CEO Daniel O'Connor has done a fantastic job at righting the ship, but this has long been the strategy at ADXS it just took a competent CEO to get it it done!
Since O'Connor came aboard, they've also recently inked a deal with $PETX which will help supplement the human indications. "...this collaboration strengthens our financial ability to further advance our proprietary immunotherapies for the treatment of human cancers."
( http://aratana.investorroom.com/2014-03-19-Aratana-and-Advaxis-Enter-Exclusive-Global-Licensing-Agreement )
Bottom line is we need something to supplement cash-flow and move forward what we have in Phase II ourselves. Moreover, I think in certain ways we have some similar strategies to ADXS and this deal is a realistic beacon of what we can look forward to as shareholders.
Merck and Advaxis team up... Advaxis to use merck's pembrolizumab
http://www.fiercebiotech.com/story/merck-and-advaxis-forge-another-no-money-down-io-development-pact/2014-08-25
I don't think this correlation applies at all and it is definitely not why I am invested in ONCS. Anyone who actually follows ONCS knows we are much closer to market than INO.
Ahab, never once did I say Punit wasn't good enough. For where this company is at he is OK. The future will tell if he is or isn't, to use your words, "good enough".
What is it that drives Punit? .....Money? Fame? Saving Lives? ...To just say success, is too broad of a statement.
You basically just made my point for me. It's all about the family $$$, not Punits resume.
To be honest I've actually often wondered if our advisory board looks down on our CEO. If any of these guys respect anything it's the technology and the future Oncosec has. I don't think that entails or validifies Punit as a legit CEO. Money can't buy respect.
I mean if you were Pierce don't you think it would be annoying to call a CEO like Punit, boss? With all of his family $$$ that allowed him to start these capital firms, obtain the CEO position and launch his ego pumping, altruistic philanthropic campaigns like Cancer Positive and YELL Canada.
Case in point, Dr.Pierce wearing jeans at a company sponsored event where Oncosec was a top level sponsor.
He's neither a doctor nor a true entrepreneur. Think about it... These doctors have worked their whole lives in oncology. When Punit was in high school most of these guys were at the frontline of the fight against cancer.
Again, this doesn't change my mind on what I've in invested in, I just want people to start painting an accurate picture of who the CEO really is, a richboy. This is fine, just don't call him dynamic, a truly dynamic CEOs body of work speaks for itself, Punits doesn't YET!
I was asking Jeff more than anyone, being that he seemingly has a closer relationship with Punit than any of us...
I have obviously read Punit's resume/bio numerous times, I want specifics as to why Jeff thinks Punit is a great CEO? So far the only things I have heard from him in light of this is that he's great because he's young, he has a finance background and he responds to people on twitter.
Go to almost any biotech CEO's resume that is comparable to ONCS and you'll find that the CEO has just as much, if not more than what Punit has on his. To say he's already a dynamic CEO is pretty pre-mature IMO, esp. when you compare him with the likes of real biotech CEO like a Joseph Kim.
But not trying to compare resumes, just feel like Jeff pumps and exaggerates the truth. I am fine being invested in a company with an "OK" CEO as long as we have people like Daud, Pierce, Ferrone and Kohrt on our side.
Jeff, really interested to know what experience Punit has that you believe is so invaluable?
The true experience in the company stems from Daud, Pierce, Ferrone, Kohrt...
Nothing like a lil PR to stem the tide!! (:
Good work furbush!
GLTA
Idc about seniority & I don't need you to validate my opinions... I've contributed my time in lobbying for us to start paying for PR (AGAIN). It's funny how many of you fail to realize ONCS paid PR is why most of us are even here.
Again, to all, I apologize if my need for integrity and responsibility has offended you. Please #%^* off!
Have a nice day!
This is what happens when you do a dilution and no one knows your company even exists. That's why the stock is overreacting in such a negative way. The only thing that could have generated new investor interest in the whole deal was to be able to say who this "highly respected" institute is and being it's less than 10% we may never know...
And no, I am not and have never suggested to release false data or whatever "IR" aka Oncosecs twitter wants to call it. I am talking about paying for legitimate promotion, because what you have with Oncosec is the potential to disrupt the market. As CEO you owe it to your shareholders and others in your company to get the respect your company deserves. Unfortunately Punit clearly failed at doing this and we will continue to suffer until he gets back from his vacation in September.
GLTA
Cool so then is it so hard to type: 'Dr. Pierce' and list his affiliation with ONCS? Instead you're hoping its insinuated. They're posting it on twitter which means anyone out there can read it. Why not have Dr Pierce, his position and accolades listed below?
If I wanted to sell I wouldn't be here lobbying to make us a stronger company... My fault, I seek responsibility. Everything I am saying is coming from an honest place, not from malice.
Guys, the point is, it's the little things we are doing wrong... Like showing up in jeans to a corporate sponsored event... Do these little things right and we'll get the recognition we all know is coming.
And I am sorry but no matter how candid Punit is perceived on twitter, social media is definitely not the place to be responding to petty shareholder questions.
Another glaring mistake.... You boast that Dr.Pierce is writing a blog yet his name is nowhere on it as author... http://oncosec.com/dna-vaccines-2014/
ONCS corporate comm is a complete joke....
It doesn't look good when you have to answer questions via twitter about Dr.Pierce leaving earlier in the day, then you later boast about a blog that is written by him yet his name is nowhere on the post...
I hate to say something like this because I really believe in the company (outside of Punit) and technology, but more and more it seems like this has scam written all over it...
Dawson stop the hate... Ignore me if you want... I along with most people here want answers and accountability, theres nothing wrong with that. Infact thats why we are all here to begin with. Clearly someone in IR is listening....
Media reports of clinical trials and new "miracle" cures can be misleading. Here are some things to consider: http://t.co/CtxmI8zwPS
— OncoSec Medical (@OncoSec) July 31, 2014
Love it! Honestly...
But the website doesn't matter, if they don't drive people to it! They need real legit, PR placements not some random blog....A Bloomberg, an MSNBC, Fox Business article, interview, mention.... anything!
The website "changed" during the week of ASCO, which did absolutely nothing for us.
Please, Jeff, please ask them why they don't retain an out of house PR firm of some kind?
Pretty simple. PR can help boost retailer confidence which can lead to many other benefits... like when you do a public offering.... Or even when you do a private placement and you test the trust of retailers by not revealing certain facts about the deal because you played into the hands of institutions. ... Do I need to continue, bc I will.
Dawson, your swiss cheese logic is not even close to reasonable..... So does not promoting the company make us NASDAQ worthy? You say "...to please OTC traders" like WE are ALL not one of them to a certain extent... hmmm
Manufacture needless PR? Are you kidding me... We did not even have one third party article on ONCS since ASCO. GTFOH.
Ya thanks Jeff (also thanks for deleting my earlier post) .... Sounds more of the same and seems to me you are just another enabler. Great effort but again you've basically just repeated the SOS.
Again if no one knows about the milestone then nothing is going to happen from a PPS standpoint. PR is a necessary part of the equation and based on results at ASCO and the fact that an insider bought in at .71 its clear that a lack of PR is exactly why we are in the .40s
Can I please rant for a minute.... Punit needs to get off twitter. Every time he opens his mouth on twitter and he isn't revealing the placement info or new data or partnership he is just killing the PPS. This type of "rogue" PR won't cut it. The company has millions in the bank and you can't afford a PR firm that runs at a lousy 5K-10k a month retainer?
Hire a damn PR firm and stop with the inane and annoyingly cheeky comments. No one gives a shit about you or your blog. We want results, not some altruistic crap about how you are the future hero in the fight against cancer.
Shit for $5k a month I may just hire a PR firm myself and pay them to publicize $ONCS. At least its better than waking up everyday with no news and losing $5k a day any ways. Anyone want to chip in with me? lol
A lot of people keep saying things about poor PR...
While I agree with that on a certain level, it just doesn't entirely feel that way to me. The pps seems to be way too manipulated to believe that this is all because of a lack of execution on the PR end. This seems to me like a textbook walk down and IMHO possibly due to the fact that we are in a 'silent period' of some kind, for whatever reason.
....To put it into perspective, I know from my own experience a decent financial PR firm costs anywhere from $5,000-$10,000 at most a month.
Do you guys all really believe that they wouldn't retain a firm because of the costs? Or what...? because management can't figure out how PR works or who the best financial/biotech PR firms are? It doesn't take a genius to figure out the right outlets.
I thought we were the only company with an MCC trial worldwide? Or is that just US...?
Add Advaxis $ADXS to the list.... Been following adxs for 2 years or so and I have to say if you want to see management screwing shareholders, go check them out.... What we've all sustained here with ONCS is nothing compared to what ADXS has done to their shareholders.
Anyways, look forward to reading your article!!! Thank you for putting in the time.
http://ir.advaxis.com/press-releases/detail/704/advaxis-and-medimmune-partner-on-immuno-oncology-combination-clinical-trial
No, it was not punit through twitter... It was Dr. Daud who made mention of FDA meeting in the Q&A session at the end of a presentation (can't remember which one) in March... And yes he went as far to specifically say "end of June." I am sure that anyone that has the time to go back to presentation transcripts between Feb. and Apr. can find it. GLTA!
I love that people are saying august will be slow. Has anyone cared to look at when inovio really ran hard for the first time after dilution? Late July - August think we are in a very similar place as they were a year ago. This pop is going to happen when people here least expect it...
Listen, I hate to bring this up again because I know people are probably tired of explaining it... But does anyone have any idea of approximately when or if we will know more about the private placement? Last I had thought I read was August 15 was the 45 day period for SEC filing.
Also, I think a lot of people here are seeing both the recent walk down and the placement and not realizing we in the .80s a relatively short time ago prior to placement. Personally, I think we are owed at least .10 here in the next few trading sessions even if we have a post presentation hangover for a couple of days.
Thanks in advance...
4:30PM - 4:45PM Gene Electrotransfer of IL-15/IL-15Ra as an Effective Immunotherapy in a Mouse Melanoma Model
SPEAKER
Dr. Richard Heller
Director and Professor, Frank Reidy Research Center for Bioelectrics
ABSTRACT
Richard Heller, Cathryn M. Lundberg, Niculina Burcus, and Shawna A. Shirley
1Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508 2Medical Diagnostics and Translational Sciences, Old Dominion University, Norfolk, VA 23508
Gene electrotransfer (GET) is a reliable and effective physical method for in vivo delivery of plasmid DNA (pDNA). Several pre-clinical and clinical studies have utilized GET to deliver genes for cancer therapy. It is particularly attractive for use in anti-cancer cytokine therapy as it does not incur the side effects associated with conventional protein cytokine therapy. Delivery of plasmids encoding cytokines directly to tumors has been shown by our lab and others to induce not only local immune response, but a systemic one as well. Previously we have shown that using GET to deliver interleukin-15 (IL-15) to mouse melanoma resulted in long term-tumor regression and survival of a percentage of treated animals after challenge. In the current study we have enhanced this anti-tumor activity by delivering both IL-15 and its soluble receptor IL-15Ra.
GET was used to deliver a plasmid encoding both IL-15 and its soluble receptor IL-15Ra to established B16.F10 tumors. Multiple delivery protocols were utilized to establish varying levels of gene expression. Plasmids expressing either IL-15 alone or IL-15Ra only were used as controls. Tumor volume was monitored for changes over a period of 9 weeks. Mice that were observed to be tumor free were then challenged with B16.F10 cells on the opposite flank and monitored for an additional 50 days. In separate experiments, protection was examined using a metastatic model. Over the course of the experiment, samples were collected for histology, IL-15 expression and cytokine analysis. Tumor regression and long- term survival in a larger percentage of animals was observed when GET was used to deliver the plasmid expressing both IL-15 and IL-15Ra compared to delivery of plasmid containing IL-15 only or simultaneous delivery of separate plasmids expressing IL-15 and IL-15Ra. After challenge, mice that were treated with the IL-15/IL-15Ra plasmid showed protection in 70% of the original treated group compared to only 30% of the group that received IL-15 only and 20% in the group that received the genes on separate plasmids. These results demonstrate that using GET to deliver IL-15/IL-15Ra a local and systemic anti- tumor immune response can be generated in a melanoma model.
http://www.isdv.org/2014/schedule/2014-dna-vaccine-conference
Agreed but he isn't speaking today.
Newly appointed Dr.Ferrone speaking in 15min...
Got it. Thanks!
Good question... I am curious as well. A lot of different opinions on here, I've seen people here say we may never know who the investors are because the deal equates to less than a 5% placement...
Also just noticed Dr. Ferrone is kicking things off July 23 with "Advances in Immunetherapy for Cancer" See link to schedule: http://www.isdv.org/2014/schedule/2014-dna-vaccine-conference
Thanks Sal and others for posting this... This sounds promising, Inovio is also presenting at this conference Inovio Upcoming Events
Obviously we all are waiting for partnership news so I am not going to speculate any more on that... But, finding out who this private placement was with will be very important for PPS and could very well answer a lot of these types of questions. I don't buy the whole "they can't explain the data" theory. They could explain it well enough to get $16million for a private placement.[img][/img]
Also, wouldn't Merck or potential partner have the people/resources to scale these trials out and 'synthesize' the data. I doubt merck or others would walk away because oncosec couldn't explain the data. Isn't that the point of getting a partner for a trial? Wouldn't Merck have their own people to do due diligence regardless of what Oncosec explained or presented to them.
Anyways, I appreciate the post; always good to talk and hear peoples theories on things.
Welcome to the board... There's been a lot of spec on the FDA meeting. It was mentioned back in April and May that FDA meeting (which is private) will be held the 2nd or 3rd week of June. People on this board have mentioned that the exact date for the meeting was June 19.
@DepthFinderX - I appreciate your contribution but its difficult for me to follow your logic. Seems to me you are speculating very, very short term PPS by using limited long term factors that are still unknown... Aren't we in the midst of two major event culminations? ...Correct me if I am wrong, but we still don't know who the private placement was with and we still have no idea what will come out of this week's FDA meeting. These two things will completely change the landscape of this company. From this point it's a waste of time to speculate what will happen with phase 3 and how ONCS will go about it until we hear from them on phase 2 & other indications like Merkel Cell.
I also think you need to reevaluate your opinion on current FDA trials for ONCS. We are not developing a drug or vaccine, this company is based on delivery technology. In my opinion, the road to market will be much sooner than 4 years.
Thank you!!! I'd imagine we'd know a little more before the shareholder meeting (7/18) but maybe that's wishful thinking.
No it wasn't Punit.... But someone from management definitely made an exact reference to at least the week it was supposed to go down. I know I saw a post with this info either on here or YMB in the past week. Going to search it and see if I can find it...
Please correct me if I am wrong but didn't someone from ONCS management say that FDA meeting was June 12 or something like that? I remember someone saying an exact date or something like the "second week of June" for FDA meeting in a presentation in the past 6 months....
Also I haven't had a chance to thoroughly review anything as far as the private placement goes, do we know what firm(s) this direct offering was with?
As some have said ASCO data could have very well been baked in, thats fine and very realistic as we're up 125%+ since January.
Sticking with my prediction from a few weeks ago on YMB: .86 close on ASCO data day, $1.20 by mid July....
ASCO Data + News from Pvt. Placement + Partnership/FDA news pending = $1.20+ by July 15.